Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

2011 ◽  
Vol 12 (9) ◽  
pp. 841-851 ◽  
Author(s):  
Hagop M Kantarjian ◽  
Andreas Hochhaus ◽  
Giuseppe Saglio ◽  
Carmino De Souza ◽  
Ian W Flinn ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Philadelphia Chromosome Positive

scholarly journals Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

2020 ◽  
Vol 189 (2) ◽  
pp. 303-312 ◽  
Author(s):  
Young Rok Do ◽  
Jae‐Yong Kwak ◽  
Jeong A. Kim ◽  
Hyeoung Joon Kim ◽  
Joo Seop Chung ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Term Data

scholarly journals Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial

2014 ◽  
Vol 168 (1) ◽  
pp. 69-81 ◽  
Author(s):  
Tim H. Brümmendorf ◽  
Jorge E. Cortes ◽  
Cármino Antonio Souza ◽  
Francois Guilhot ◽  
Ladan Duvillié ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document